Literature DB >> 17174102

Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study.

Maria Caterina Grassi1, Anna Maria Cioce, Franco Dei Giudici, Letizia Antonilli, Paolo Nencini.   

Abstract

Cocaine abusers frequently report taking the drug in association with alcohol. This combined intake leads to the synthesis of cocaethylene, an active metabolite with effects similar to those of cocaine, but more prolonged. Since pharmacological effects of cocaethylene may partially account for the habit of cocaine abusers to take the drug in combination with ethanol, a main therapeutic goal in these patients should be making body fluids negative for cocaethylene. This randomized controlled open study conducted on 12 subjects co-abusers of cocaine and alcohol, evaluates the efficacy of a 12-week pharmacological treatment with Disulfiram (DIS) 400mg daily or Naltrexone (NTX) 50mg daily associated with Cognitive Behaviour Therapy (CBT), as compared to CBT alone, in terms of: (i) stay in treatment; (ii) drug-free urinalyses for cocaine and cocaethylene; (iii) reduction of alcohol and cocaine craving. Data presented in this study are restricted to the first 4 weeks of treatment when all the enrolled subjects were still available for examination. In fact, of the 12 subjects enrolled in the study only 4 (33%) completed the 12-week treatment. Of these, three were in the CBT group and one in the NTX/CBT group. Results show that CBT treated subjects remained in treatment longer than those assigned to either DIS/CBT or NTX/CBT therapies. However, during the first 4 weeks of treatment, CBT-group urine tested positive almost always for both cocaine and cocaethylene. In contrast, both DIS/CBT and NTX/CBT treatments were associated to a statistically significant reduction, of positive urinalysis for both cocaine and cocaethylene, with respect to CBT alone. Moreover, across the first 4 weeks of treatment DIS/CBT and NTX/CBT treated subjects maintained lower scores at Visual Analogue Scales (VAS) for both cocaine and alcohol craving than subjects receiving CBT alone. This pilot study suggests that the transient efficacy of pharmacological treatments in maintaining subjects drug free, does not add to the capability of CBT to retain them in treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174102     DOI: 10.1016/j.phrs.2006.11.005

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  17 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

2.  A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.

Authors:  Helen M Pettinati; Kyle M Kampman; Kevin G Lynch; Hu Xie; Charles Dackis; Amanda R Rabinowitz; Charles P O'Brien
Journal:  Addict Behav       Date:  2007-11-17       Impact factor: 3.913

3.  Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.

Authors:  Sarah Sushchyk; Zheng-Xiong Xi; Jia Bei Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-02-22       Impact factor: 4.030

Review 4.  Topiramate in the treatment of substance-related disorders: a critical review of the literature.

Authors:  Ann K Shinn; Shelly F Greenfield
Journal:  J Clin Psychiatry       Date:  2010-03-09       Impact factor: 4.384

5.  Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase.

Authors:  Jason P Schroeder; Debra A Cooper; Jesse R Schank; Megan A Lyle; Meriem Gaval-Cruz; Yvonne E Ogbonmwan; Nikita Pozdeyev; Kimberly G Freeman; P Michael Iuvone; Gaylen L Edwards; Philip V Holmes; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

6.  Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Authors:  Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

Review 7.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

8.  High-dose naltrexone therapy for cocaine-alcohol dependence.

Authors:  Joy M Schmitz; Jan A Lindsay; Charles E Green; David V Herin; Angela L Stotts; F Gerard Moeller
Journal:  Am J Addict       Date:  2009 Sep-Oct

9.  Dopamine β-hydroxylase inhibitors enhance the discriminative stimulus effects of cocaine in rats.

Authors:  Daniel F Manvich; Lauren M DePoy; David Weinshenker
Journal:  J Pharmacol Exp Ther       Date:  2013-09-25       Impact factor: 4.030

Review 10.  The impact of cigarette smoking on stimulant addiction.

Authors:  Andrea H Weinberger; Mehmet Sofuoglu
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.